vs
Side-by-side financial comparison of Anteris Technologies Global Corp. (AVR) and Inogen Inc (INGN). Click either name above to swap in a different company.
Inogen Inc is the larger business by last-quarter revenue ($68.6M vs $310.0K, roughly 221.2× Anteris Technologies Global Corp.). Inogen Inc produced more free cash flow last quarter ($-1.9M vs $-18.9M).
Anteris Technologies Global Corp is a medical technology firm specializing in innovative structural heart care solutions. It develops and commercializes bioprosthetic heart valves and transcatheter intervention products, serving healthcare providers across North America, Europe, and Asia-Pacific, with core focus on cardiac surgery and interventional cardiology segments.
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
AVR vs INGN — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $310.0K | $68.6M |
| Net Profit | $-29.2M | — |
| Gross Margin | 70.6% | 51.4% |
| Operating Margin | -9343.5% | -13.6% |
| Net Margin | -9420.0% | — |
| Revenue YoY | — | 3.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.74 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $310.0K | $68.6M | ||
| Q3 25 | $429.0K | $79.1M | ||
| Q2 25 | $618.0K | $79.2M | ||
| Q1 25 | $556.0K | $68.5M | ||
| Q4 24 | — | $66.3M | ||
| Q3 24 | — | $74.9M | ||
| Q2 24 | — | $74.4M | ||
| Q1 24 | — | $63.1M |
| Q4 25 | $-29.2M | — | ||
| Q3 25 | $-22.2M | $-5.3M | ||
| Q2 25 | $-20.8M | $-4.2M | ||
| Q1 25 | $-21.9M | $-6.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-6.0M | ||
| Q2 24 | — | $-5.6M | ||
| Q1 24 | — | $-14.6M |
| Q4 25 | 70.6% | 51.4% | ||
| Q3 25 | 71.3% | 52.2% | ||
| Q2 25 | 76.1% | 52.2% | ||
| Q1 25 | 62.8% | 53.1% | ||
| Q4 24 | — | 54.7% | ||
| Q3 24 | — | 55.2% | ||
| Q2 24 | — | 57.4% | ||
| Q1 24 | — | 54.5% |
| Q4 25 | -9343.5% | -13.6% | ||
| Q3 25 | -5190.0% | -9.0% | ||
| Q2 25 | -3379.3% | -7.7% | ||
| Q1 25 | -3917.3% | -11.2% | ||
| Q4 24 | — | -17.2% | ||
| Q3 24 | — | -10.4% | ||
| Q2 24 | — | -9.5% | ||
| Q1 24 | — | -25.8% |
| Q4 25 | -9420.0% | — | ||
| Q3 25 | -5185.1% | -6.7% | ||
| Q2 25 | -3371.2% | -5.2% | ||
| Q1 25 | -3932.4% | -9.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -8.0% | ||
| Q2 24 | — | -7.5% | ||
| Q1 24 | — | -23.1% |
| Q4 25 | $-0.74 | $-0.26 | ||
| Q3 25 | $-0.62 | $-0.20 | ||
| Q2 25 | $-0.58 | $-0.15 | ||
| Q1 25 | $-0.61 | $-0.25 | ||
| Q4 24 | — | $-0.41 | ||
| Q3 24 | — | $-0.25 | ||
| Q2 24 | — | $-0.24 | ||
| Q1 24 | — | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $103.7M |
| Total DebtLower is stronger | $22.0K | — |
| Stockholders' EquityBook value | $-93.0K | $192.2M |
| Total Assets | $23.0M | $298.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $103.7M | ||
| Q3 25 | — | $106.5M | ||
| Q2 25 | — | $103.7M | ||
| Q1 25 | $49.0M | $118.9M | ||
| Q4 24 | — | $113.8M | ||
| Q3 24 | — | $105.7M | ||
| Q2 24 | — | $97.9M | ||
| Q1 24 | — | $107.4M |
| Q4 25 | $22.0K | — | ||
| Q3 25 | $26.0K | — | ||
| Q2 25 | $30.0K | — | ||
| Q1 25 | $30.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-93.0K | $192.2M | ||
| Q3 25 | $3.7M | $197.2M | ||
| Q2 25 | $24.4M | $199.5M | ||
| Q1 25 | $43.3M | $198.0M | ||
| Q4 24 | — | $173.9M | ||
| Q3 24 | — | $185.4M | ||
| Q2 24 | — | $187.6M | ||
| Q1 24 | — | $191.9M |
| Q4 25 | $23.0M | $298.6M | ||
| Q3 25 | $19.1M | $307.0M | ||
| Q2 25 | $39.9M | $312.0M | ||
| Q1 25 | $58.8M | $308.4M | ||
| Q4 24 | — | $296.2M | ||
| Q3 24 | — | $306.2M | ||
| Q2 24 | — | $308.9M | ||
| Q1 24 | — | $315.6M |
| Q4 25 | — | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.5M | $-943.0K |
| Free Cash FlowOCF − Capex | $-18.9M | $-1.9M |
| FCF MarginFCF / Revenue | -6104.5% | -2.8% |
| Capex IntensityCapex / Revenue | 128.1% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-79.8M | $-13.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.5M | $-943.0K | ||
| Q3 25 | $-18.3M | $2.2M | ||
| Q2 25 | $-19.5M | $4.3M | ||
| Q1 25 | $-21.5M | $-16.8M | ||
| Q4 24 | — | $-3.0M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $6.7M | ||
| Q1 24 | — | $-4.7M |
| Q4 25 | $-18.9M | $-1.9M | ||
| Q3 25 | $-19.0M | $1.6M | ||
| Q2 25 | $-20.1M | $3.7M | ||
| Q1 25 | $-21.7M | $-17.1M | ||
| Q4 24 | — | $-3.3M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | — | $6.6M | ||
| Q1 24 | — | $-6.1M |
| Q4 25 | -6104.5% | -2.8% | ||
| Q3 25 | -4434.5% | 2.0% | ||
| Q2 25 | -3247.9% | 4.6% | ||
| Q1 25 | -3909.5% | -24.9% | ||
| Q4 24 | — | -5.0% | ||
| Q3 24 | — | 7.1% | ||
| Q2 24 | — | 8.9% | ||
| Q1 24 | — | -9.6% |
| Q4 25 | 128.1% | 1.4% | ||
| Q3 25 | 180.0% | 0.7% | ||
| Q2 25 | 86.9% | 0.9% | ||
| Q1 25 | 44.6% | 0.4% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 2.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
